Your browser doesn't support javascript.
loading
Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens.
Antanasijevic, Aleksandar; Ueda, George; Brouwer, Philip J M; Copps, Jeffrey; Huang, Deli; Allen, Joel D; Cottrell, Christopher A; Yasmeen, Anila; Sewall, Leigh M; Bontjer, Ilja; Ketas, Thomas J; Turner, Hannah L; Berndsen, Zachary T; Montefiori, David C; Klasse, Per Johan; Crispin, Max; Nemazee, David; Moore, John P; Sanders, Rogier W; King, Neil P; Baker, David; Ward, Andrew B.
Affiliation
  • Antanasijevic A; Department of Integrative, Structural and Computational Biology, Scripps Research, La Jolla, California, United States of America.
  • Ueda G; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research, La Jolla, California, United States of America.
  • Brouwer PJM; Institute for Protein Design, Department of Biochemistry, University of Washington, Seattle, Washington, United States of America.
  • Copps J; Academic Medical Center (AMC), University of Amsterdam, Amsterdam, Netherlands.
  • Huang D; Department of Integrative, Structural and Computational Biology, Scripps Research, La Jolla, California, United States of America.
  • Allen JD; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research, La Jolla, California, United States of America.
  • Cottrell CA; Department of Immunology and Microbiology, Scripps Research, La Jolla, California, United States of America.
  • Yasmeen A; School of Biological Sciences, University of Southampton, Southampton, United Kingdom.
  • Sewall LM; Department of Integrative, Structural and Computational Biology, Scripps Research, La Jolla, California, United States of America.
  • Bontjer I; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research, La Jolla, California, United States of America.
  • Ketas TJ; Weill Cornell Medicine, Cornell University, New York, New York, United States of America.
  • Turner HL; Department of Integrative, Structural and Computational Biology, Scripps Research, La Jolla, California, United States of America.
  • Berndsen ZT; Academic Medical Center (AMC), University of Amsterdam, Amsterdam, Netherlands.
  • Montefiori DC; Weill Cornell Medicine, Cornell University, New York, New York, United States of America.
  • Klasse PJ; Department of Integrative, Structural and Computational Biology, Scripps Research, La Jolla, California, United States of America.
  • Crispin M; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research, La Jolla, California, United States of America.
  • Nemazee D; Department of Integrative, Structural and Computational Biology, Scripps Research, La Jolla, California, United States of America.
  • Moore JP; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research, La Jolla, California, United States of America.
  • Sanders RW; Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.
  • King NP; Weill Cornell Medicine, Cornell University, New York, New York, United States of America.
  • Baker D; School of Biological Sciences, University of Southampton, Southampton, United Kingdom.
  • Ward AB; Department of Immunology and Microbiology, Scripps Research, La Jolla, California, United States of America.
PLoS Pathog ; 16(8): e1008665, 2020 08.
Article in En | MEDLINE | ID: mdl-32780770
ABSTRACT
Two-component, self-assembling nanoparticles represent a versatile platform for multivalent presentation of viral antigens. Computational design of protein nanoparticles with differing sizes and geometries enables combination with antigens of choice to test novel multimerization concepts in immunization strategies where the goal is to improve the induction and maturation of neutralizing antibody lineages. Here, we describe detailed antigenic, structural, and functional characterization of computationally designed tetrahedral, octahedral, and icosahedral nanoparticle immunogens displaying trimeric HIV envelope glycoprotein (Env) ectodomains. Env trimers, based on subtype A (BG505) or consensus group M (ConM) sequences and engineered with SOSIP stabilizing mutations, were fused to an underlying trimeric building block of each nanoparticle. Initial screening yielded one icosahedral and two tetrahedral nanoparticle candidates, capable of presenting twenty or four copies of the Env trimer. A number of analyses, including detailed structural characterization by cryo-EM, demonstrated that the nanoparticle immunogens possessed the intended structural and antigenic properties. When the immunogenicity of ConM-SOSIP trimers presented on a two-component tetrahedral nanoparticle or as soluble proteins were compared in rabbits, the two immunogens elicited similar serum antibody binding titers against the trimer component. Neutralizing antibody titers were slightly elevated in the animals given the nanoparticle immunogen and were initially more focused to the trimer apex. Altogether, our findings indicate that tetrahedral nanoparticles can be successfully applied for presentation of HIV Env trimer immunogens; however, the optimal implementation to different immunization strategies remains to be determined.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Antibodies / HIV Antigens / HIV Infections / HIV-1 / Nanoparticles / Env Gene Products, Human Immunodeficiency Virus Type of study: Evaluation_studies Limits: Animals / Female / Humans Language: En Journal: PLoS Pathog Year: 2020 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Antibodies / HIV Antigens / HIV Infections / HIV-1 / Nanoparticles / Env Gene Products, Human Immunodeficiency Virus Type of study: Evaluation_studies Limits: Animals / Female / Humans Language: En Journal: PLoS Pathog Year: 2020 Document type: Article Affiliation country: